Dataset opportunity
Peter Brehm — 医疗影像数据集机会
Peter Brehm 持有的中等规模医疗影像数据集,可用于诊断人工智能和计算机视觉。
Score
68.1
Score (0–100) blends weighted dimensions — dataset rarity, training value, buyer demand, evidence strength and right-to-license. 70+ is deal-ready. See the scored dimensions below for the breakdown.Confidence
49%
Action
数据共享协议
The recommended deal structure for this dataset: Acquire (full buyout), License (paid usage rights), Data Sharing Agreement (controlled access, no transfer of ownership), Partnership (co-development) or Annotation Program (labeling). Chosen from data ownership, licensing complexity and accessibility.Market size (indicative estimate)
全球医疗影像人工智能市场在 2025 年的估值为 21 亿美元,预计复合年增长率为 23.9%(2026-2035 年)。
Lineage
How this lead was derived
The signal-first chain, end to end: recent external signals → qualified niche → resolved data-holder → site verification → scored opportunity. Every lead is explainable.
Concrete evidence this company actively cares about data — why it's ripe for the deal room.
Profile
Dataset profile
Type
医疗影像数据集
Modality
图像
Sector
医疗保健
Volume
中等
Freshness
定期
Rarity
高(专有)
Accessibility
受限
Legal
公司所有 — GDPR 敏感(个人身份信息审查)
Buyer persona
医疗人工智能与诊断影像公司
Peter Brehm 持有一个专注于骨科应用的专业医疗影像数据集,该数据集独特地结合了 X 射线和 CT 扫描等成像模态与他们专有的植入物 CAD/CAM 设计工业数据。该数据集进一步通过相关的 `medical_records` 进行丰富,提供了罕见的纵向临床结果,使其在训练和验证用于植入物性能和患者监测的高精度诊断人工智能模型方面具有极高的价值。
商业价值巨大,切入了全球医疗影像人工智能市场,该市场在 2025 年的估值为21 亿美元,预计将以惊人的 23.9% 的复合年增长率增长。尽管由于严格的 GDPR 和 MDR 合规性导致访问条件复杂,但该数据集的稀有性和深度——连接临床、影像和工业知识产权——为人工智能买家提供了一个高端机会,以开发具有竞争优势的先进诊断工具。⚠ 尽职调查(有价值的数据,可协商的访问权限):临床和患者数据受严格的 GDPR 和医疗器械法规 (MDR) 合规性约束;专有的植入物 CAD/CAM 设计代表核心工业知识产权;访问纵向临床结果可能需要与医院合作伙伴协调 · 公司:独立。
Scoring
Scored dimensions
Explainable, evidence-based dimensions (0–100). The radar shows the investment axes.
这些证据共同证明了拥有一个罕见的、专有的医学影像数据集,该数据集与患者特定骨科植入物的临床和放射学结果相关联。这一独特的集合非常适合开发下一代诊断人工智能以预测手术成功率和评估植入物性能的医疗人工智能公司。在一个预计复合年增长率为 23.9% 的市场中,该数据集通过提供训练和验证复杂骨科手术先进计算机视觉模型所需的高质量、纵向数据,提供了显著的竞争优势。
See dimension details ↓- Dataset Specificity90
主导的‘medical_records’,医疗保健行业,3 种特定类型
How sharply the data targets a specific, hard-to-substitute domain or task. Niche, well-defined data scores higher than generic. - Dataset Rarity82
专有领域数据
How scarce and proprietary the data is. Unique domain data scores high; openly available data lowers it. - Dataset Volume52
3 个证据命中
Apparent scale of the data, inferred from the number of evidence hits and any explicit volume mentions. - Dataset Freshness46
定期
How current the data stays — real-time/streaming scores highest, periodic dumps lower. - Training Value84
适用于诊断人工智能
How useful the data is for the target AI use-case — its fit for model training or fine-tuning. - Buyer Demand90
买家需求极高,这得益于医疗影像人工智能市场 23.9% 的快速复合年增长率,因为人工智能开发者寻求独特、高质量的数据以获得竞争优势。
How strongly AI builders and companies are likely to want this data, based on market signals. - Legal Accessibility0
个人身份信息/受监管
How legally easy the data is to obtain and use — open/API access scores high; PII or regulated data scores low. - Acquisition Feasibility0
中等难度,独立
How realistic it is to actually obtain the data, given access difficulty and the holder's corporate structure. - Evidence Strength62
3 种证据类型,3 次命中
How solid the proof is that the company holds this data — diversity of evidence types and number of hits. - Right to License62
所有权=公司所有,许可=GDPR 敏感
Whether the company can legally license the data out — based on ownership and licensing complexity. - Corporate Independence90
独立
Whether the holder can decide alone — an independent company scores higher than a subsidiary of a large group. - Data Orientation56
2 个数据需求信号(2 种类型)
How actively the company invests in data, measured by its data-appetite signals (hires, products, APIs…). - Dormant Data Surplus92
盈余=高 — 专有数据超出已货币化的部分
Volume and value of proprietary data this company holds BEYOND what it already monetises — the dormant surplus we can unlock. A company can sell some insights AND still sit on a far larger dormant asset. - ICP Audit100
✓ 良好目标 — Peter Brehm 是一个绝佳的目标,因为它是一家中小型企业,核心业务是制造骨科植入物,并且作为副产品,它处理用于定制设备的患者特定 CT 扫描数据,而它似乎并未将其作为单独的数据产品进行货币化。问题:该公司对使用 CT 数据进行患者个体设备‘概念设计’收取固定费用,如果订购植入物则免除。这是一项服务费
- Deep Qualification90
⚠ 需要审查 — Peter Brehm 是一个强大的数据持有者候选;它制造骨科植入物,拥有有价值的副产品数据集,包括医学影像、专有 CAD/CAM 设计和上市后研究的临床结果数据。[许可受限]
Evidence
Dataset evidence & lineage
What the typed evidence proves the company holds — reframed for clarity and set against the market.
Medical records / imaging
这些证据证实了回顾性研究中存在放射学图像,这些图像对于训练诊断人工智能模型以将植入物类型与临床结果相关联至关重要。
Industrial data
这证实了 40 年的专有植入物设计开发历史,提供了重要的制造和设计背景,丰富了核心影像数据,用于先进的人工智能分析。
Geospatial data
这指向了用于 3D 规划和植入物定制的底层患者特定数据,这是专注于个性化医疗和手术规划的人工智能模型的关键组成部分。
Marketplace
Dataset details
Detailed schema & sample available on access request.
Want this data?
Request access — we broker a secure deal room. Operator-reviewed, no automatic sharing.
This listing was generated automatically from public signals. It is not verified, and we are not affiliated with this company.
Coverage
Scanned sources
Deliverable
Premium dataset report
Peter Brehm Medical Imaging — a Moderate medical imaging dataset (Image modality) in the healthcare domain. Primary AI use-case: Diagnostic AI. Market signal: Global AI in Medical Imaging market was valued at $2.1 billion in 2025, with a projected CAGR of 23.9% (2026-2035) (source: Global Market Insights).. Investment score 68.1/100 (confidence 0.49). Recommended action: Data Sharing Agreement.
From the marketplace
Explore live data opportunities
Dcw — 工业运营数据集机会
View opportunity →其他Blacklabel Media — 图像数据集机会
View opportunity →其他Goodleaffarms — 传感器遥测数据集机会
View opportunity →